The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease
Open accessAbstract
The identification and cloning of the two major cannabinoid (CB¬1 and CB2) receptors together with the discovery of their endogenous ligands in the late 80s and early 90s, resulted in a major effort aimed at understanding the mechanisms and physiological roles of the endocannabinoid system (ECS). Due to its expression and localization in the central nervous system (CNS), the CB1 receptor together with its endogenous ligands (endocannabinoids) and the enzymes involved in their synthesis and degradation, has been implicated in multiple pathophysiological events ranging from memory deficits to neurodegenerative disorders among others. In this review, we will provide a general overview of the endocannabinoid system with emphasis on the CB1 receptor in health and disease. We will describe our current understanding of the complex aspects of receptor signaling and trafficking, including the non-canonical signaling pathways such as those mediated by β-arrestins within the context of functional selectivity and ligand bias. Finally, we will highlight some of the disorders in which CB1 receptors have been implicated. Significant knowledge has been achieved over the last 30 years. However, much more research is still needed to fully understand the complex roles of the endocannabinoid system, particularly in vivo, and to unlock its true potential as a source of therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Endocannabinoid Signaling and Synaptic Function
Castillo, P. E., Younts, T. J., Chávez, A. E., & Hashimotodani, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.020 · Cited by 1,120
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Structure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 944
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & de Ceballos, M. L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 785
ENDOCANNABINOID-MEDIATED SYNAPTIC PLASTICITY IN THE CNS
Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112834 · Cited by 783
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Crystal Structure of the Human Cannabinoid Receptor CB1
Hua, T., Vemuri, K., Pu, M., Qu, L., Han, G. W., Wu, Y., Zhao, S., Shui, W., Li, S., Korde, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.004 · Cited by 673
Cannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Glass, M., & Felder, C. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-14-05327.1997 · Cited by 635
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
Mackie, K., Lai, Y., Westenbroek, R., & Mitchell, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06552.1995 · Cited by 626
Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., Strachan, R. T., Huang, T.-Y., Bressler, E. A., Hara, M. R., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001707 · Cited by 626
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608
Involvement of the endocannabinoid system in drug addiction
Maldonado, R., Valverde, O., & Berrendero, F. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.008 · Cited by 580
GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling
Thomsen, A. R. B., Plouffe, B., Cahill, T. J., Shukla, A. K., Tarrasch, J. T., Dosey, A. M., Kahsai, A. W., Strachan, R. T., Pani, B., Mahoney, J. P., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.004 · Cited by 563
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
Twitchell, W., Brown, S., & Mackie, K. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.78.1.43 · Cited by 544
Cannabinoids control spasticity and tremor in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 532
Jiang, W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25509 · Cited by 527
Glass, M., Dragunow, M., & Faull, R. L. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00008-7 · Cited by 483
Endocannabinoid Signaling and Long-Term Synaptic Plasticity
Heifets, B. D., & Castillo, P. E. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163149 · Cited by 482
Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., & Frank, R. A. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.4.322 · Cited by 481
Endocannabinoid signalling in reward and addiction
Parsons, L. H., & Hurd, Y. L. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4004 · Cited by 481
Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22330 · Cited by 461
Cannabinoid Receptor Signaling
Howlett, A. C. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_2 · Cited by 446
Atwood, B. K., Lopez, J., Wager-Miller, J., Mackie, K., & Straiker, A. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-14 · Cited by 424
Demuth, D. G., & Molleman, A. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.055 · Cited by 420
Principles: Receptor theory in pharmacology
Kenakin, T. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.012 · Cited by 412
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397
Endocannabinoid signalling and the deteriorating brain
Di Marzo, V., Stella, N., & Zimmer, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3876 · Cited by 382
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382
Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P., Ledent, C., Cheng, X., Carrier, E. J., Mann, M. K., et al. (2007) · Nature Medicine · doi:10.1038/nm1561 · Cited by 363
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C., Petzold, A., Thompson, A. J., Giovannoni, G., et al. (2003) · Brain · doi:10.1093/brain/awg224 · Cited by 342
Pregnenolone Can Protect the Brain from Cannabis Intoxication
Vallée, M., Vitiello, S., Bellocchio, L., Hébert-Chatelain, E., Monlezun, S., Martin-Garcia, E., Kasanetz, F., Baillie, G. L., Panin, F., Cathala, A., et al. (2014) · Science · doi:10.1126/science.1243985 · Cited by 319
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
Arévalo-Martı́n, Á., Vela, J. M., Molina-Holgado, E., Borrell, J., & Guaza, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02511.2003 · Cited by 314
Endocannabinoids and Their Pharmacological Actions
Pertwee, R. G. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-20825-1_1 · Cited by 300
Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298
Agonist Selective Regulation of G Proteins by Cannabinoid CB1 and CB2 Receptors
Glass, M., & Northup, J. K. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12404-2 · Cited by 298
Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus
Stempel, A. V., Stumpf, A., Zhang, H.-Y., Özdoğan, T., Pannasch, U., Theis, A.-K., Otte, D.-M., Wojtalla, A., Rácz, I., Ponomarenko, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.034 · Cited by 292
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.
Little, P. J., Compton, D. R., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13256-4 · Cited by 291
Hart, S., Fischer, O. M., & Ullrich, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3720 · Cited by 288
Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization
Jin, W., Brown, S., Roche, J. P., Hsieh, C., Celver, J. P., Kovoor, A., Chavkin, C., & Mackie, K. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-10-03773.1999 · Cited by 261
Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0025-1 · Cited by 252
Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents
Brenneisen, R. (2007) · Forensic Science And Medicine · doi:10.1007/978-1-59259-947-9_2 · Cited by 251
Therapeutic Potential of Cannabinoids in CNS Disease
Croxford, J. L. (2003) · CNS Drugs · doi:10.2165/00023210-200317030-00004 · Cited by 240
Multiple Signaling States of G-Protein-Coupled Receptors
Perez, D. M., & Karnik, S. S. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.2 · Cited by 237
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
Aso, E., & Ferrer, I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00037 · Cited by 237
Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor
Leterrier, C., Bonnard, D., Carrel, D., Rossier, J., & Lenkei, Z. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403990200 · Cited by 236
Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling
Dudok, B., Barna, L., Ledri, M., Szabó, S. I., Szabadits, E., Pintér, B., Woodhams, S. G., Henstridge, C. M., Balla, G. Y., Nyilas, R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3892 · Cited by 227
Regulation of PI3K/Akt/GSK‐3 pathway by cannabinoids in the brain
Ozaita, A., Puighermanal, E., & Maldonado, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04642.x · Cited by 216
Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease
Mulder, J., Zilberter, M., Pasquaré, S. J., Alpár, A., Schulte, G., Ferreira, S. G., Köfalvi, A., Martín-Moreno, A. M., Keimpema, E., Tanila, H., et al. (2011) · Brain · doi:10.1093/brain/awr046 · Cited by 210
GPCR signaling along the endocytic pathway
Irannejad, R., & von Zastrow, M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.10.003 · Cited by 204
Differential G-protein-coupled Receptor Phosphorylation Provides Evidence for a Signaling Bar Code
Butcher, A. J., Prihandoko, R., Kong, K. C., McWilliams, P., Edwards, J. M., Bottrill, A., Mistry, S., & Tobin, A. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154526 · Cited by 202
Depolarization‐induced suppression of excitation in murine autaptic hippocampal neurones
Straiker, A., & Mackie, K. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.091918 · Cited by 201
Leterrier, C., Lainé, J., Darmon, M., Boudin, H., Rossier, J., & Lenkei, Z. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5437-05.2006 · Cited by 201
The CB1 Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase
Rueda, D., Galve-Roperh, I., Haro, A., & Guzmán, M. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23114-x · Cited by 200
Guo, J., & Ikeda, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.665 · Cited by 190
Cannabinoid Control of Learning and Memory through HCN Channels
Maroso, M., Szabo, G. G., Kim, H. K., Alexander, A., Bui, A. D., Lee, S.-H., Lutz, B., & Soltesz, I. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.023 · Cited by 189
Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities
Bosier, B., Muccioli, G. G., Hermans, E., & Lambert, D. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.02.013 · Cited by 188
The endocannabinoid system as a target for the treatment of neurodegenerative disease
Scotter, E. L., Abood, M. E., & Glass, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00735.x · Cited by 179
Anti-inflammatory lipoxin A 4 is an endogenous allosteric enhancer of CB 1 cannabinoid receptor
Pamplona, F. A., Ferreira, J., Menezes de Lima, O., Duarte, F. S., Bento, A. F., Forner, S., Villarinho, J. G., Bellocchio, L., Wotjak, C. T., Lerner, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202906109 · Cited by 179
The endocannabinoid system in normal and pathological brain ageing
Bilkei‐Gorzó, A. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0388 · Cited by 179
Neuromodulatory functions of the endocannabinoid system.
Marsicano, G., & Lutz, B. (2006) · PubMed · Cited by 172
Wade, D. T., Collin, C., Stott, C. G., & Duncombe, P. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510367462 · Cited by 168
Endocannabinoids and traumatic brain injury
Shohami, E., Cohen‐Yeshurun, A., Magid, L., Algali, M., & Mechoulam, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01343.x · Cited by 168
Notcutt, W., Langford, R., Davies, P., Ratcliffe, S., & Potts, R. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511419700 · Cited by 165
Otero-Romero, S., Sastre-Garriga, J., Comi, G., Hartung, H.-P., Soelberg Sørensen, P., Thompson, A. J., Vermersch, P., Gold, R., & Montalban, X. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516643600 · Cited by 162
Regulation of CB 1 cannabinoid receptor trafficking by the adaptor protein AP‐3
Rozenfeld, R., & Devi, L. A. (2008) · The FASEB Journal · doi:10.1096/fj.07-102731 · Cited by 160
Cannabinoids activate p38 mitogen‐activated protein kinases through CB1 receptors in hippocampus
Derkinderen, P., Ledent, C., Parmentier, M., & Girault, J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00333.x · Cited by 159
Alzheimer's disease; taking the edge off with cannabinoids?
Campbell, V. A., & Gowran, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707446 · Cited by 157
Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy
Soltész, I., Alger, B. E., Kano, M., Lee, S.-H., Lovinger, D. M., Ohno‐Shosaku, T., & Watanabe, M. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn3937 · Cited by 157
Expression of functional cannabinoid CB 2 receptor in VTA dopamine neurons in rats
Zhang, H., Gao, M., Shen, H., Bi, G., Yang, H., Liu, Q., Wu, J., Gardner, E. L., Bonci, A., & Xi, Z. (2016) · Addiction Biology · doi:10.1111/adb.12367 · Cited by 157
Endogenous cannabinoids revisited: A biochemistry perspective
Fonseca, B. M., Costa, M. A., Almada, M., Correia‐da‐Silva, G., & Teixeira, N. A. A. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.02.002 · Cited by 155
Martini, L., Waldhoer, M., Pusch, M., Kharazia, V., Fong, J. C., Lee, J. H., Freissmuth, C., & Whistler, J. L. (2006) · The FASEB Journal · doi:10.1096/fj.06-7132com · Cited by 152
The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
Blázquez, C., Chiarlone, A., Bellocchio, L., Resel, E., Pruunsild, P., García-Rincón, D., Sendtner, M., Timmusk, T., Lutz, B., Galve‐Roperh, I., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.11 · Cited by 150
Phosphorylation Barcoding as a Mechanism of Directing GPCR Signaling
Liggett, S. B. (2011) · Science Signaling · doi:10.1126/scisignal.2002331 · Cited by 147
Ahn, K. H., Mahmoud, M. M., Shim, J., & Kendall, D. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438804 · Cited by 145
Self-citationMechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength
Mackie, K. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803273 · Cited by 144
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 142
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., Dupré, D. J., & Denovan‐Wright, E. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557025 · Cited by 141
Prospects for cannabinoid therapies in basal ganglia disorders
Fernández‐Ruíz, J., Moreno‐Martet, M., Rodríguez‐Cueto, C., Palomo‐Garo, C., Gómez‐Cañas, M., Valdeolivas, S., Guaza, C., Romero, J., Guzmán, M., Mechoulam, R., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01365.x · Cited by 136
Park, P. S.-H., Lodowski, D. T., & Palczewski, K. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094630 · Cited by 131
Marsicano, G., & Kuner, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_10 · Cited by 126
Endocannabinoids and Traumatic Brain Injury
Mechoulam, R., & Shohami, E. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-8008-6 · Cited by 123
Cannabinoids and Neuroprotection in Basal Ganglia Disorders
Sagredo, O., García-Arencibia, M., de Lago, E., Finetti, S., Decio, A., & Fernández‐Ruíz, J. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0004-3 · Cited by 115
Mechanisms of Biased β-Arrestin-Mediated Signaling Downstream from the Cannabinoid 1 Receptor
Delgado‐Peraza, F., Ahn, K. H., Nogueras‐Ortiz, C. J., Mungrue, I. N., Mackie, K., Kendall, D. A., & Yudowski, G. A. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.103176 · Cited by 115
Self-citationNguyen, P., Schmid, C. L., Raehal, K. M., Selley, D. E., Bohn, L., & Sim‐Selley, L. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.027 · Cited by 113
Intracellular Cannabinoid Type 1 (CB1) Receptors Are Activated by Anandamide
Brailoiu, G. C., Oprea, T. I., Zhao, P., Abood, M. E., & Brailoiu, E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217463 · Cited by 108
Wu, D., Yang, L., Goschke, A., Stumm, R. K., Brandenburg, L., Liang, Y.-J., Höllt, V., & Koch, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05063.x · Cited by 107
Valdeolivas, S., Satta, V., Pertwee, R. G., Fernández‐Ruíz, J., & Sagredo, O. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200114w · Cited by 107
Persistent cAMP Signaling by Internalized LH Receptors in Ovarian Follicles
Lyga, S., Volpe, S., Werthmann, R. C., Götz, K. R., Sungkaworn, T., Lohse, M. J., & Calebiro, D. (2015) · Endocrinology · doi:10.1210/en.2015-1945 · Cited by 107
McCaw, E. A., Hu, H., Gomez, G. T., Hebb, A. L. O., Kelly, M. E. M., & Denovan‐Wright, E. M. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04460.x · Cited by 106
Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1
Flores‐Otero, J., Ahn, K. H., Delgado‐Peraza, F., Mackie, K., Kendall, D. A., & Yudowski, G. A. (2014) · Nature Communications · doi:10.1038/ncomms5589 · Cited by 101
Self-citationLaprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.101980 · Cited by 100
The Multiple Waves of Cannabinoid 1 Receptor Signaling
Nogueras‐Ortiz, C. J., & Yudowski, G. A. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104539 · Cited by 93
Self-citationLópez-Rodríguez, A. B., Siopi, E., Finn, D. P., Marchand‐Leroux, C., García‐Segura, L. M., Jafarian-Tehrani, M., & Viveros, M. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht202 · Cited by 92
Nie, J., & Lewis, D. L. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-22-08758.2001 · Cited by 88
McDonald, N. A., Henstridge, C. M., Connolly, C. N., & Irving, A. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.029348 · Cited by 87
Gruenbaum, S. E., Zlotnik, A., Gruenbaum, B. F., Hersey, D., & Bilotta, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0355-2 · Cited by 86 · cited 5×
“There is an ‘‘on-demand’’ signal to generate eCB following TBI that can decrease brain edema and inflammation (Shohami et al., 2011; Gruenbaum et al., 2016).”
BackgroundInfluentialTrazzi, S., Steger, M., Mitrugno, V. M., Bartesaghi, R., & Ciani, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.043711 · Cited by 83
Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation
Jackson, S. J., Pryce, G., Diemel, L. T., Cuzner, M. L., & Baker, D. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.02.045 · Cited by 82
Cannabinoid Modulation of Neuroinflammatory Disorders
Saito, V. M., Rezende, R. M., & Teixeira, A. L. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604515 · Cited by 75
Dowie, M. J., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.06.056 · Cited by 74
Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
Liu, C. S., Chau, S. A., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2015) · CNS Drugs · doi:10.1007/s40263-015-0270-y · Cited by 71
Roche, J. P., Bounds, S., Brown, S. M., & Mackie, K. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.611 · Cited by 68
Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2−/− mice
Breivogel, C. S., Lambert, J. M., Gerfin, S., Huffman, J. W., & Razdan, R. K. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328308f1e6 · Cited by 66
Worsening of Huntington disease phenotype in CB1 receptor knockout mice
Mievis, S., Blum, D. L., & Ledent, C. A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.006 · Cited by 65
Differential Activation of Intracellular versus Plasmalemmal CB2 Cannabinoid Receptors
Brailoiu, G. C., Deliu, E., Marcu, J. P., Hoffman, N. E., Console‐Bram, L., Zhao, P., Madesh, M., Abood, M. E., & Brailoiu, E. (2014) · Biochemistry · doi:10.1021/bi500632a · Cited by 64
Prihandoko, R., Alvarez‐Curto, E., Hudson, B. D., Butcher, A. J., Ulven, T., Miller, A. M., Tobin, A. B., & Milligan, G. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.101949 · Cited by 62
Eldeeb, K., Leone‐Kabler, S., & Howlett, A. C. (2016) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2015-0096 · Cited by 59
Stumm, C., Hiebel, C., Hanstein, R., Purrio, M., Nagel, H., Conrad, A., Lutz, B., Behl, C., & Clement, A. B. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.027 · Cited by 54
Type I Cannabinoid Receptor Trafficking: All Roads Lead to Lysosome
Rozenfeld, R. (2010) · Traffic · doi:10.1111/j.1600-0854.2010.01130.x · Cited by 51
Cannabis-based medicines in multiple sclerosis – A review of clinical studies
Rog, D. J. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.03.009 · Cited by 45
Straiker, A. J., Wager‐Miller, J., Hutchens, J. M., & Mackie, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01744.x · Cited by 43
Mutations in the ‘DRY’ motif of the CB1 cannabinoid receptor result in biased receptor variants
Gyombolai, P., Tóth, A. D., Tímár, D., Turu, G., & Hunyady, L. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0219 · Cited by 37
Fu, W., & Taylor, B. K. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.04.002 · Cited by 31
Behavioral Methods in Cannabinoid Research
Fride, E., Perchuk, A., Hall, F. S., Uhl, G. R., & Onaivi, E. S. (2006) · Humana Press eBooks · doi:10.1385/1-59259-999-0:269 · Cited by 31
Varvel, S. A., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0811-2 · Cited by 23
Breivogel, C. S., & Vaghela, M. S. (2015) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2014.1003659 · Cited by 17
Cited by
Phytocannabinoids: Origins and Biosynthesis
Gülck, T., & Møller, B. L. (2020) · Trends in Plant Science · doi:10.1016/j.tplants.2020.05.005 · Cited by 392
CB 1 and CB 2 Receptor Pharmacology
Howlett, A. C., & Abood, M. E. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.03.007 · Cited by 375
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Liu, Q.-R., Canseco-Alba, A., Zhang, H.-Y., Tagliaferro, P., Chung, M., Dennis, E., Sanabria, B., Schanz, N., Escosteguy-Neto, J. C., Ishiguro, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17796-y · Cited by 147
Metadata
- Authors
- Kendall, D. A., & Yudowski, G. A.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-01-04
- Volume
- 10
- Pages
- 294-294
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W2565813493
- Cited by
- 359
- References
- 127
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.